Progressive Supranuclear Palsy
FDA grants fast-track designation to injectable positron emission tomography diagnostic
The FDA has granted fast-track designation to an investigational tau positron emission tomography diagnostic that can be used for a range of neurodegenerative conditions, according to the manufacturer.
FDA grants fast track designation to PET tau imaging tracer
The FDA has granted fast track designation to a radioactive fluorinated positron emission tomography tracer for imaging tau protein in those with suspected progressive supranuclear palsy, according to the manufacturer.
Amylyx pulls ALS drug Relyvrio from market in US, Canada
Amylyx Pharmaceuticals Inc. announced Relyvrio, its amyotrophic lateral sclerosis therapeutic, will be removed from the market in the United States and Canada, effective immediately.
Frontotemporal lobar degeneration-associated syndromes common across Europe
The incidence of frontotemporal labor degeneration-associated disorders is more common in Europe than previously thought, with an estimated 12,057 new cases per year, researchers reported in JAMA Neurology.
MRI findings key pathology markers of 4R-tauopathies
SEATTLE — MRI biomarkers were significantly associated with glial tau pathology and could aid in the diagnosis of certain neurodegenerative diseases, a presenter said at the 2022 American Academy of Neurology annual meeting.